ERBB2 and neoplasm: To this end, we analyzed eight HER2-positive breast tumor samples from patients who had completed two or more cycles of neoadjuvant trastuzumab and evaluated the genomic features of these tumors with a focus on the PD-1 positive tumor immune environment.